source
- FDA reverses earlier stance, grants uniQure accelerated approval pathway for Huntington's gene therapyOn June 17, 2026, the U.S. Food and Drug Administration issued a second reversal, allowing biotech company uniQure to pursue an accelerated approval pathway for its gene therapy targeting Huntingto…
- Jazz partners with AbCellera on $4 billion deal to develop next-generation T-cell engagers for solid tumorsJazz Pharmaceuticals disclosed a collaboration with AbCellera aimed at creating next-generation T-cell-engaging antibodies for solid tumors. Under the agreement Jazz will pay $56 million up front…